Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27903858 | 0.98 | EPHX1 (0.35) | EPHX1NCF1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14311906 | 0.84 | SLC6A2 (0.36) | EPHX1NCF1SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL14311983 | 0.82 | ALDH1A1 (0.38) | EPHX1NCF1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15592009 | 0.82 | ALDH1A1 (0.40) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL14311988 | 0.78 | EPHX1 (0.35) | EPHX1NCF1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL23269569 | 0.78 | EPHX1 (0.38) | EPHX1NCF1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL19781548 | 0.78 | EPHX1 (0.38) | EPHX1NCF1SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL14311817 | 0.77 | EPHX1 (0.34) | EPHX1NCF1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14888125 | 0.76 | SLC6A2 (0.37) | EPHX1SLC6A2SLC6A4SLC6A3SMN1; SMN2 | |
| SCHEMBL24733196 | 0.76 | EPHX1 (0.35) | EPHX1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | EPHX1 2695/4885NCF1 1608/4885SLC6A2 4707/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | EPHX1 2695/4885NCF1 1608/4885SLC6A2 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.